

**ThinkEquity,**  
**A Division of Fordham Financial Management, Inc**  
17 State Street, 22nd Floor  
New York, New York 10004

October 30, 2020

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

**Re:    Inhibikase Therapeutics, Inc. (the “Company”)**  
**Registration Statement on Form S-1, as amended (the “Registration Statement”)**  
**File No. 333-240036**

Ladies and Gentlemen:

On October 27, 2020, ThinkEquity, a division of Fordham Financial Management, Inc. (“**ThinkEquity**”), as representative of the underwriters of the offering, joined in the request of the Company that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so as to permit it to become effective on Thursday, October 29, 2020, at 5:00 p.m. (Eastern Time), or as soon thereafter as practicable. The undersigned, on behalf of ThinkEquity, hereby withdraws such request.

Very truly yours,

ThinkEquity,  
a division of Fordham Financial Management, Inc.

By:    /s/ Eric Lord  
Name: Eric Lord  
Title: Head of Investment Banking

cc: Leslie Marlow, Esq.  
Patrick J. Egan, Esq.

---